AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment

被引:29
|
作者
Falster, Kathleen [1 ,2 ]
Choi, Jun Yong [3 ]
Donovan, Basil [1 ,4 ]
Duncombe, Chris [1 ,5 ]
Mulhall, Brian [6 ]
Sowden, David [7 ]
Zhou, Jialun [1 ]
Law, Matthew G. [1 ]
机构
[1] Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
[3] Yonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea
[4] Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW, Australia
[5] HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[6] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[7] Sunshine Coast & Cooloola HIV Sexual Hlth Serv, Clin 87, Nambour, Qld, Australia
基金
美国国家卫生研究院;
关键词
AIDS; antiretroviral therapy; causes of death; cohort studies; competing-risks models; highly active; HIV; survival analysis; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; BASE-LINE; THERAPY; DEATH; RISK; SEROCONVERSION; INDIVIDUALS; DISEASE; BURDEN;
D O I
10.1097/QAD.0b013e328331910c
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Although studies have shown reductions in mortality from AIDS after the introduction of combination antiretroviral treatment (cART), little is known about cause-specific mortality in low-income settings in the cART era. We explored predictors of AIDS and non-AIDS mortality and compared cause-specific mortality across high-income and low-income settings in the Asia-Pacific region. Methods: We followed patients in the Asia Pacific HIV Observational Database from the date they started cART (or cohort enrolment if cART initiation was identified retrospectively), until the date of death or last follow-up visit. Competing risks methods were used to estimate the cumulative incidence, and to investigate predictors, of AIDS and non-AIDS mortality. Results: Of 4252 patients, 215 died; 89 from AIDS, 97 from non-AIDS causes and 29 from unknown causes. Age more than 50 years [hazard ratio 4.29; 95% confidence interval (CI) 2.10-8.79] and CD4 cell counts less than or equal to 100 cells/mu l (hazard ratio 8.59; 95%% CI 5.66-13.03) were associated with an increased risk of non-AIDS mortality. Risk factors for AIDS mortality included CD4 cell counts less than or equal to 100 cells/mu l (hazard ratio 34.97; 95% CI 18.01-67.90) and HIV RNA 10001 or more (hazard ratio 4.21; 95% CI 2.07-8.55). There was some indication of a lower risk of non-AIDS mortality in Asian high-income, and possibly low-income, countries compared to Australia. Conclusion: Immune deficiency is associated with an increased risk of AIDS and non-AIDS mortality. Older age predicts non-AIDS mortality in the cART era. Less conclusive was the association between country-income level and cause-specific mortality because of the relatively high proportion of unknown causes of death in low-income settings. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:2323 / 2336
页数:14
相关论文
共 50 条
  • [21] AIDS-Related Vs. Non-AIDS-Related Diffuse Large B-Cell Lymphoma. Analysis of the County Hospital AIDS Malignancy Project (CHAMP)
    Petrowski, Kelly A.
    Poola, Harsha
    Chuy, Katherine Lee
    Gupta, Shweta
    Rubinstein, Paul G.
    BLOOD, 2015, 126 (23)
  • [22] AIDS-related opportunistic illness and potent antiretroviral therapy
    Engels, EA
    Frisch, M
    Biggar, RJ
    Goedert, JJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (20): : 2653 - 2653
  • [23] FANSIDAR - A TREATMENT FOR AIDS-RELATED PNEUMOCYSTIS
    BATH, PMW
    LILLICRAP, DA
    WINTER, M
    POSTGRADUATE MEDICAL JOURNAL, 1987, 63 (740) : 509 - 510
  • [24] THYMOSTIMULIN TREATMENT IN AIDS-RELATED COMPLEX
    PALMISANO, L
    CHISESI, T
    GALLI, M
    GRITTI, FM
    IELASI, G
    LAZZARIN, A
    MEZZAROMA, I
    MORONI, M
    RAISE, E
    VAGLIA, A
    AIUTI, F
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1988, 47 (03): : 253 - 261
  • [25] Evidence of AIDS-related mortality in Mumbai, India
    Hira, SK
    Rao, ASRS
    Thanekar, J
    LANCET, 1999, 354 (9185): : 1175 - 1176
  • [26] Treatment options of AIDS-related lymphoma
    Schmidt-Wolf, IGH
    Rockstroh, JK
    Schlegel, U
    Pels, H
    Mey, U
    Strehl, J
    Weiss, R
    Huhn, D
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (08) : 1331 - 1343
  • [27] TREATMENT OF AIDS-RELATED KAPOSIS SARCOMA
    不详
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1989, 46 (06): : 1211 - 1211
  • [28] THE TREATMENT OF AIDS-RELATED LYMPHOMA - REPLY
    LEVINE, AM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (04): : 510 - 510
  • [29] New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy
    Holland, GN
    OCULAR IMMUNOLOGY AND INFLAMMATION, 1999, 7 (3-4) : 179 - 188
  • [30] Clinical and inununologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy
    Barclay, Lindsay R.
    Buskin, Susan E.
    Kahle, Erin M.
    Aboulafia, David M.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (04): : 272 - 279